QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

GMAB

QT53Genmab A/S
NASDAQ·Healthcare·Biotechnology·DK
Latest market price
25.27
-0.12-0.47%
OverviewShort InterestFilings
GMABQT53Genmab A/S·NASDAQ
OverviewShort InterestFilings
25.27-0.47%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E19.04EPS (ttm)
1.32
Insider Own-
Shs Outstand62.35M
Perf Week0.12%
Market Cap15.62BForward P/E15.10EPS next Y1.67Insider Trans-Shs Float-Perf Month-1.60%
Enterprise Value19.45BPEG-EPS next Q0.34Inst Own-Short Float-Perf Quarter-1.79%
Income820.22MP/S1.66EPS this Y-12.70%Inst Trans-Short Ratio-Perf Half Y-19.39%
Sales9.40BP/B2.75EPS next Y45.24%ROA6.63%Short Interest-Perf YTD-17.95%
Book/sh91.13P/C17.28EPS next 5Y23.59%ROE14.53%52W High35.43 -28.68%Perf Year14.71%
Cash/sh24.39P/FCF17.88EPS past 3/5Y-ROIC8.89%52W Low20.23 24.91%Perf 3Y-
Dividend Est.-EV/EBITDA13.79Sales past 3/5Y-36.45% -18.11%Gross Margin38.65%Volatility1.92% 2.18%Perf 5Y-
Dividend TTM-EV/Sales2.07EPS Y/Y TTM-88.55%Oper. Margin13.67%ATR (14)0.75Perf 10Y-
Dividend Ex-Date-Quick Ratio2.17Sales Y/Y TTM-81.88%Profit Margin8.73%RSI (14)47.23Recom2.00
Dividend Gr. 3/5Y-Current Ratio2.18EPS Q/Q-51.61%SMA20-0.64%Beta0.82Target Price38.30
Payout0.00%Debt/Eq0.94Sales Q/Q756.19%SMA50-4.72%Rel Volume0.95Prev Close25.39
Employees2,638LT Debt/Eq0.88EarningsAug 06SMA200-13.67%Avg Volume1.90MPrice25.27
IPO DateJun 01, 2009Option/ShortYes / YesEPS/Sales Surpr.0.00% -1.10%Net Debt/EBITDA2.72Volume1,809,877Change-0.47%
Analyst Ratings
DateActionAnalystRatingTarget
May-27-26ReiteratedTruist Financial$48 → $40
Apr-30-26ReiteratedH.C. WainwrightBuy$40 → $38
Mar-26-26InitiatedWolfe ResearchOutperform$32
Feb-23-26ReiteratedGuggenheimBuy$43 → $40
Feb-17-26ResumedJefferiesBuy$42
Jan-20-26ReiteratedH.C. WainwrightBuy$41 → $39
Nov-06-25ReiteratedTruist Financial$49 → $48
Oct-06-25ReiteratedTruist Financial$46 → $49
Oct-02-25ReiteratedH.C. WainwrightBuy$36 → $40
Sep-29-25ReiteratedLeerink PartnersOutperform$32 → $34
Latest News
Jun-15-26
Jun-15-2604:04PM
Major Shareholder AnnouncementYahoo
12:10PM
Genmab Discloses Orbis Investment Management Holds 4.99% Voting Rights Stake Of The Company As Of June 12, 2026Benzinga
10:07AM
Genmab’s EPCORE Data Deepens Lymphoma Profile As Investors Weigh UpsideYahoo
03:13AM
Reported Saturday, Genmab's Epcoritamab Monotherapy Achieves 67% ORR And 58% CR Rate While Combination With R-Mini-CHOP Delivers 93% ORR And 86% CR In Elderly Newly Diagnosed DLBCL PatientsBenzinga
Jun-13-26
Jun-13-2604:45PM
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Yahoo
Jun-11-26
Jun-11-2605:17PM
Grant of Restricted Stock Units and Warrants to Employees in GenmabYahoo
02:45PM
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) PatientsYahoo
10:47AM
Genmab Data From Pivotal Phase 3 EPCORE FL-1 Study Of Epcoritamab In Combination With Rituximab And Lenalidomide Demonstrates Consistent, Sustained Efficacy Benefits Throughout Clinically Relevant SubgroupsBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,9013,72321,526
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A261309985
Gross Profit3,6403,41420,541
Selling, General and Administrative Excl. Other6666023,790
Research and Development1,6871,5609,748
Other Operating Expense01300
Operating Income1,2871,2516,703
Interest Expense16861120
Unusual Expense
———
Non-Operating Income (Expense)85-15-2,581
Net Income Before Taxes1,0341,2059,164
Income Taxes2132411,320
Consolidated Net Income8219647,844
Net Income From Continuing Operations8219647,844
Net Income8219647,844
EPS (Recurring)1.331.5512.14
EPS (Basic, Before Extraordinaries)1.331.5512.14
EPS (Diluted)1.321.5412.14
EBITDA1,2371,3379,697
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio19.1420.00—
Price To Sales Ratio3.985.15—
Gross Margin93.3191.7095.42
Operating Margin32.9933.6031.14
Net Margin21.0525.8936.44
Shares Outstanding614622646
Market Capitalization15,51619,158—
Operating Lease Expense
———
Insider Trading Volume
$26.47$24.20$21.94$19.67$17.40● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR